Cantor Fitzgerald Reiterates Overweight Rating for COMPASS Pathways (NASDAQ:CMPS)

COMPASS Pathways (NASDAQ:CMPS)‘s stock had its “overweight” rating reissued by Cantor Fitzgerald in a report issued on Thursday, Benzinga reports.

CMPS has been the subject of a number of other reports. Morgan Stanley initiated coverage on shares of COMPASS Pathways in a research report on Monday, April 1st. They issued an “overweight” rating and a $30.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $120.00 price target on shares of COMPASS Pathways in a research report on Friday, March 1st. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $47.40.

COMPASS Pathways Stock Performance

Shares of CMPS opened at $8.38 on Thursday. The company has a 50-day moving average of $9.94 and a two-hundred day moving average of $8.35. The company has a debt-to-equity ratio of 0.14, a current ratio of 13.33 and a quick ratio of 13.33. The stock has a market cap of $519.06 million, a price-to-earnings ratio of -3.51 and a beta of 2.48. COMPASS Pathways has a one year low of $5.01 and a one year high of $12.75.

COMPASS Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Thursday, February 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.16). On average, equities research analysts expect that COMPASS Pathways will post -2.4 earnings per share for the current year.

Insider Activity at COMPASS Pathways

In related news, Director Ekaterina Malievskaia sold 19,853 shares of the firm’s stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $10.59, for a total transaction of $210,243.27. Following the transaction, the director now owns 4,144,994 shares of the company’s stock, valued at $43,895,486.46. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, Director Ekaterina Malievskaia sold 19,853 shares of COMPASS Pathways stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $10.59, for a total value of $210,243.27. Following the transaction, the director now owns 4,144,994 shares of the company’s stock, valued at $43,895,486.46. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director George Jay Goldsmith sold 15,740 shares of COMPASS Pathways stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $10.58, for a total transaction of $166,529.20. Following the completion of the transaction, the director now directly owns 4,079,107 shares in the company, valued at approximately $43,156,952.06. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 166,351 shares of company stock valued at $1,553,923. 23.99% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On COMPASS Pathways

A number of institutional investors have recently modified their holdings of CMPS. Vivo Capital LLC bought a new position in shares of COMPASS Pathways in the third quarter valued at approximately $11,899,000. RA Capital Management L.P. acquired a new stake in shares of COMPASS Pathways in the third quarter worth $9,516,000. Affinity Asset Advisors LLC acquired a new stake in shares of COMPASS Pathways in the fourth quarter worth $4,812,000. Armistice Capital LLC acquired a new stake in shares of COMPASS Pathways in the third quarter worth $2,960,000. Finally, Laurion Capital Management LP grew its stake in shares of COMPASS Pathways by 169.7% in the third quarter. Laurion Capital Management LP now owns 510,907 shares of the company’s stock worth $3,781,000 after acquiring an additional 321,500 shares during the last quarter. Institutional investors own 46.19% of the company’s stock.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.